
Many Americans battling diabetes are turning to a new class of injected drugs that includes blockbusters like Ozempic (semaglutide) and Mounjaro (tirzepatide). But a new study finds half of patients who use these “second line” therapies — a class called GLP-1 RAs — quit them within a year. The main factor: Gastrointestinal issues like nausea, vomiting… read on > read on >